Loading company
Latest annual · FY2025
Millions- Total revenues
- 146
- Operating income
- (91)
- Net income
- (196)
- Free cash flow
- (75)
Latest quarter · Q2 FY2026
Millions- Total revenues
- 33
- Operating income
- (23)
- Net income
- (67)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -2.4%
- Revenue, 5 yearsFY2020 to FY2025
- +6.2%
- Net income, 5 yearsFY2020 to FY2025
- n/m
Karyopharm Therapeutics Inc. (KPTI) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $146.1 million | $145.2 million | +0.6% | 10-K 2026-02-13 · proof |
| Operating income | -$90.7 million | -$119.4 million | 10-K 2026-02-13 · proof | |
| Net income | -$196 million | -$76.4 million | 10-K 2026-02-13 · proof | |
| Cash from operating activities | -$75.4 million | -$127.5 million | 10-K 2026-02-13 · proof | |
| Free cash flow | -$75.4 million | -$127.6 million | 10-K 2026-02-13 · proof |
- What was Karyopharm Therapeutics Inc. (KPTI)'s revenue in fiscal 2025?
- Karyopharm Therapeutics Inc. (KPTI) reported revenue of $146.1 million for fiscal 2025 (the year ended Dec 31, 2025), against $145.2 million the year before (+0.6%). Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
- What was Karyopharm Therapeutics Inc. (KPTI)'s operating income in fiscal 2025?
- Karyopharm Therapeutics Inc. (KPTI) reported operating income of -$90.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$119.4 million the year before. Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
- What was Karyopharm Therapeutics Inc. (KPTI)'s net income in fiscal 2025?
- Karyopharm Therapeutics Inc. (KPTI) reported net income of -$196 million for fiscal 2025 (the year ended Dec 31, 2025), against -$76.4 million the year before. Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
- What was Karyopharm Therapeutics Inc. (KPTI)'s cash from operating activities in fiscal 2025?
- Karyopharm Therapeutics Inc. (KPTI) reported cash from operating activities of -$75.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$127.5 million the year before. Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
- What was Karyopharm Therapeutics Inc. (KPTI)'s free cash flow in fiscal 2025?
- Karyopharm Therapeutics Inc. (KPTI) reported free cash flow of -$75.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$127.6 million the year before. Source: the 10-K filed with the SEC on Feb 13, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:KPTI&period_type=annual&limit=5"Information only, not investment advice.